Evidence map›Paper›PMID 30854224›Full record

ArticleNPJ systems biology and applications2019

Erratum: Publisher Correction: Mathematical model of hemodynamic mechanisms and consequences of glomerular hypertension in diabetic mice.

Hari Shankar Mahato, Christine Ahlstrom, Rasmus Jansson-Löfmark, Ulrika Johansson, Gabriel Helmlinger, K Melissa Hallow

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in NPJ systems biology and applications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Hari Shankar MahatoSchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, GA, USA.ORCID http://orcid.org/0000-0002-9187-8091
Christine AhlstromDrug Metabolism and Pharmacokinetics, Cardiovascular, Renal, and Metabolism, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Rasmus Jansson-LöfmarkDrug Metabolism and Pharmacokinetics, Cardiovascular, Renal, and Metabolism, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Ulrika JohanssonBioscience Chronic Kidney Disease, Cardiovascular, Renal, and Metabolism Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Gabriel HelmlingerQuantitative Clinical Pharmacology, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Waltham, MA, USA.
K Melissa HallowSchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, GA, USA. hallowkm@uga.edu.
AstraZeneca (Sweden) · SEUniversity of Georgia · USAstraZeneca (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.1038/s41540-018-0077-9.].

Identifiers

PMID30854224
PMCPMC6399214
OpenAlexW2919959225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.